0001626199-21-000130.txt : 20210927
0001626199-21-000130.hdr.sgml : 20210927
20210927070220
ACCESSION NUMBER: 0001626199-21-000130
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210923
FILED AS OF DATE: 20210927
DATE AS OF CHANGE: 20210927
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CONWAY ROBERT E
CENTRAL INDEX KEY: 0001184334
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37449
FILM NUMBER: 211278983
MAIL ADDRESS:
STREET 1: C/O ARCA BIOPHARMA, INC
STREET 2: 8001 ARISTA PLACE, STE 430
CITY: BROOMFIELD
STATE: CO
ZIP: 80021
FORMER NAME:
FORMER CONFORMED NAME: CONWAY ROBERT
DATE OF NAME CHANGE: 20020829
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC.
CENTRAL INDEX KEY: 0001626199
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208969493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-788-4545
MAIL ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Nivalis Therapeutics, Inc.
DATE OF NAME CHANGE: 20150211
FORMER COMPANY:
FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141121
4/A
1
wf-form4a_163274052780471.xml
FORM 4/A
X0306
4/A
2021-09-23
2021-09-24
0
0001626199
ALPINE IMMUNE SCIENCES, INC.
ALPN
0001184334
CONWAY ROBERT E
C/O ALPINE IMMUNE SCIENCES, INC.
188 EAST BLAINE STREET, SUITE 200
SEATTLE
WA
98102
1
0
0
0
Common Stock
2021-09-23
4
P
0
15000
10.0769
A
50000
I
By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust
The Form 4 filed on September 24, 2021 inadvertently included an incorrect transaction code for the reported transaction. The transaction code included on the original Form 4 was "S" while the correct transaction code should have been "P".
This transaction was executed in multiple trades at prices ranging from $9.945 to $10.20. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
/s/ James Paul Rickey, attorney-in-fact
2021-09-27